 




<RINDOCK>[Docket No. 94N0167]</RINDOCK>



<DOCTITLE>Drug Export; Estrapel (Estradiol) Pellets 25 mg</DOCTITLE>


<AGENCY>
AGENCY:

 Food and Drug Administration, HHS.


</AGENCY>
<ACTION>
ACTION:

 Notice.




</ACTION>
<SUMMARY>
SUMMARY:

 The Food and Drug Administration (FDA) is announcing that Bartor Pharmacal Co., Inc., has filed an application requesting
conditional approval for the export of the human drug Estrapel (estradiol) Pellets 25 milligrams (mg) to Great Britain.


</SUMMARY>
<ADDRESS>
ADDRESSES:

 Relevant information on this application may be directed to the Dockets Management Branch (HFA305), Food
and Drug Administration, rm. 123, 12420 Parklawn Dr., Rockville, MD 20857, and to the contact person identified
below. Any future inquiries concerning the export of human drugs under the Drug Export Amendments Act of 1986 should
also be directed to the contact person.


</ADDRESS>
<FURTHER>
FOR FURTHER INFORMATION CONTACT: 


James E. Hamilton, 
Center for Drug Evaluation and Research (HFD313), 
Food and Drug Administration, 
5600 Fishers Lane, 
Rockville, MD 20857, 
3015942073. 

</FURTHER>
<SUPPLEM>
SUPPLEMENTARY INFORMATION:

 The drug export provisions in section 802 of the Federal Food, Drug, and Cosmetic Act (the act) (21 U.S.C. 382) provide
that FDA may approve applications for the export of drugs that are not currently approved in the United States. Section
802(b)(3)(B) of the act sets forth the requirements that must be met in an application for approval. Section 802(b)(3)(C)
of the act requires that the agency review the application within 30 days of its filing to determine whether the requirements
of section 802(b)(3)(B) have been satisfied. Section 802(b)(3)(A) of the act requires that the agency publish a notice
in the 

Federal Register

 within 10 days of the filing of an application for export to facilitate public participation in its review of the application.
To meet this requirement, the agency is providing notice that Bartor Pharmacal Co., Inc., 70 High St., Rye, NY 10580,
has filed an application requesting conditional approval for the export of the human drug Estrapel (estradiol) Pellets
25 mg to Great Britain. Estrapel (estradiol) Pellets 25 mg is indicated for major post-menopausal symptoms due to
estrogen deficiency, including prevention of post-menopausal osteoporosis in hysterectomized patients. The
application was received and filed in the Center for Drug Evaluation and Research on April 5, 1994, which shall be considered
the filing date for purposes of the act.


Interested persons may submit relevant information on the application to the Dockets Management Branch (address
above) in two copies (except that individuals may submit single copies) and identified with the docket number found
in brackets in the heading of this document. These submissions may be seen in the Dockets Management Branch between
9 a.m. and 4 p.m., Monday through Friday.
The agency encourages any person who submits relevant information on the application to do so by May 23, 1994, and to
provide an additional copy of the submission directly to the contact person identified above, to facilitate consideration
of the information during the 30-day review period.
This notice is issued under the Federal Food, Drug, and Cosmetic Act (sec. 802 (21 U.S.C. 382)) and under authority
delegated to the Commissioner of Food and Drugs (21 CFR 5.10) and redelegated to the Center for Drug Evaluation and
Research (21 CFR 5.44).




Dated: May 3, 1994.

</SUPPLEM>
<SIGNER>
Stephanie R. Gray,

</SIGNER>
<SIGNJOB>
Acting Director, Office of Compliance, Center for Drug Evaluation and Research.

</SIGNJOB>
<FRFILING>
[FR Doc. 9411642 Filed 51294; 8:45 am]

</FRFILING>
<BILLING>
BILLING CODE 416001F
</BILLING>


